Home › Funds › Ikarian Capital, LLC › JBIO

Ikarian Capital, LLC position in JBIO

JADE BIOSCIENCES INC · Health Care

Ikarian Capital, LLC reported holding 427,349 shares of JBIO (JADE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$9.5M, representing 1.52% of its reported portfolio and ranking #19 among its reported holdings. Ikarian Capital, LLC has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)427.35K sh
Reported value held$9.50M
Portfolio Weight1.52%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Ikarian Capital, LLC's JBIO position evolved

Ikarian Capital, LLC first disclosed a stake in JBIO in Q4 2025 at 300,000 shares (US$4.6M). The position peaked in Q2 2026 at 427,349 shares, worth US$9.5M. Across 3 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 427,349 shares valued at US$9.5M — a reduction of -85,000 shares quarter over quarter.. Notable position changes include a 71% increase in Q1 2026 (shares rose 58% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 300.00K $4.63M New
Q1 2026 512.35K $7.20M Add
Q2 2026 427.35K $9.50M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JBIO and 13F data

JBIO (JADE BIOSCIENCES INC) is a Health Care company. 106 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JBIO

All JBIO fund holders →

FAQ

How long has Ikarian Capital, LLC held JBIO?

Ikarian Capital, LLC has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Ikarian Capital, LLC's current position in JBIO?

As of Q2 2026, Ikarian Capital, LLC holds 427.35K shares of JBIO (JADE BIOSCIENCES INC), valued at $9.50M, representing 1.52% of its reported portfolio and ranking #19.

Has Ikarian Capital, LLC been buying or selling JBIO?

In the latest 13F filing (Q2 2026), Ikarian Capital, LLC reduced its position in JBIO. The position peaked in Q2 2026 at 427.35K shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 106 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.